ABSTRACT
Objective@#To explore the therapeutic effect of bismuth potassium citrate combined with famotidine on peptic ulcer and its effects on the levels of lipid peroxide (LPO), malondialdehyde (MDA) and somatostatin (SS).@*Methods@#One hundred and fifty patients with peptic ulcer who were treated in Cixi Cilin Hospital from January 2018 to May 2019 were randomly divided into famotidine group and combined treatment group, with 75 cases in each group. Famotidine group was treated with famotidine, while bismuth potassium citrate combined with famotidine was used in combined treatment group. H+-K+-ATP ase activity, gastric acid-base value and gastric acid secretion function were detected in two groups. The levels of tumor necrosis factor-α (TNF-α), interleukin-7 (IL-7), hypersensitive C-reactive protein (hs-CRP) were detected by ELISA, T lymphocyte subsets were detected by flow cytometry, and the levels of T lymphocyte subsets were detected by immunotransmission turbidimetry. The levels of LPO, MDA and SS were measured, and the therapeutic effect, ulcer healing and adverse reactions were compared between two groups.@*Results@#After treatment, the activity of H+-K+-ATP ase in the combined treatment group was lower than that in the famotidine group [(2.54 ± 0.41) μmol/min vs. (2.87 ± 0.50) μmol/min], the acid-base value in stomach was higher than that in the famotidine group(5.56 ± 1.19 vs. 4.77 ± 0.89), and there were significant differences (P<0.05). After treatment, the levels of maximum gastric acid excretion after pentagastrin stimulation (MAO), peak gastric acid output (PAO), basal acid output (BAO), TNF-α, IL-17, hs-CRP, CD8+, LPO and MDA in combined treatment group were lower than those in famotidine group [(8.22 ± 1.76) mmol/h vs. (10.53 ± 2.21) mmol/h, (11.88 ± 2.51)mmol/h vs. (14.79 ± 2.76) mmol/h, (4.11 ± 1.32) mmol/h vs. (5.54 ± 1.49) mmol/h, (4.76 ± 1.52) ng/L vs.(6.91 ± 1.61) ng/L, (18.37 ± 3.25) ng/L vs. (22.83 ± 3.62) ng/L, (6.41 ± 1.81) mg/L vs. (8.67 ± 2.15) mg/L, 0.287 6 ± 0.030 5 vs. 0.325 5 ± 0.032 4, (0.06 ± 0.02) U/mg vs. (0.09 ± 0.03) U/mg, (10.19 ± 1.86) μmol/L vs. (13.25 ± 2.03) μmol/L], while the levels of CD3+, CD4+, SS were higher than those in the famotidine group [0.523 6 ± 0.040 9 vs. 0.476 3 ± 0.039 5, 0.356 6 ± 0.035 2 vs. 0.315 8 ± 0.033 9, (14.59 ± 2.67) ng/L vs. (10.36 ± 2.31) ng/L], and there were significant differences (P<0.05). The total effective rate and ulcer healing rate in combined treatment group were higher than those in famotidine group [93.33%(70/75) vs. 80.00%(60/75), 94.67%(71/75) vs. 82.67%(62/75)] (P<0.05). The incidence of adverse reactions in combined treatment group was slightly higher than that in famotidine group [16.00%(12/75) vs. 13.33%(10/75)], but there was no significant difference between the two groups (P>0.05).@*Conclusions@#Bismuth potassium citrate combined with famotidine in the treatment of peptic ulcer patients can improve gastric acid secretion function, regulate gastric acid-base value, inhibit inflammatory response, improve immune function, and reduce oxidative stress injury.
ABSTRACT
Objective To explore the therapeutic effect of bismuth potassium citrate combined with famotidine on peptic ulcer and its effects on the levels of lipid peroxide (LPO),malondialdehyde (MDA) and somatostatin (SS).Methods One hundred and fifty patients with peptic ulcer who were treated in Cixi Cilin Hospital from January 2018 to May 2019 were randomly divided into famotidine group and combined treatment group,with 75 cases in each group.Famotidine group was treated with famotidine,while bismuth potassium citrate combined with famotidine was used in combined treatment group.H+-K+-ATP ase activity,gastric acid-base value and gastric acid secretion function were detected in two groups.The levels of tumor necrosis factor-ot (TNF-α),interleukin-7 (IL-7),hypersensitive C-reactive protein (hs-CRP) were detected by ELISA,T lymphocyte subsets were detected by flow cytometry,and the levels of T lymphocyte subsets were detected by immunotransmission turbidimetry.The levels of LPO,MDA and SS were measured,and the therapeutic effect,ulcer healing and adverse reactions were compared between two groups.Results After treatment,the activity of H+-K+-ATP ase in the combined treatment group was lower than that in the famotidine group [(2.54 ± 0.41) μmol/min vs.(2.87 ± 0.50) μmol/min],the acid-base value in stomach was higher than that in the famotidine group (5.56 ± 1.19 vs.4.77 ± 0.89),and there were significant differences (P ＜ 0.05).After treatment,the levels of maximum gastric acid excretion after pentagastrin stimulation (MAO),peak gastric acid output (PAO),basal acid output (BAO),TNF-α,IL-17,hs-CRP,CD8+,LPO and MDA in combined treatment group were lower than those in famotidine group [(8.22 ± 1.76) mmol/h vs.(10.53 ± 2.21) mmol/h,(11.88 ± 2.51)mmol/h vs.(14.79 ± 2.76) mmol/h,(4.11 ± 1.32) mmol/h vs.(5.54 ± 1.49) mmol/h,(4.76 ± 1.52) ng/L vs.(6.91 ± 1.61) ng/L,(18.37 ± 3.25) ng/L vs.(22.83 ± 3.62) ng/L,(6.41 ± 1.81) mg/L vs.(8.67 ± 2.15) mg/L,0.287 6 ± 0.030 5 vs.0.325 5 ± 0.032 4,(0.06 ± 0.02) U/mg vs.(0.09 ± 0.03) U/mg,(10.19 ± 1.86) μmol/L vs.(13.25 ± 2.03) μmol/L],while the levels of CD3+,CD4+,SS were higher than those in the famotidine group [0.523 6 ± 0.040 9 vs.0.476 3 ± 0.039 5,0.356 6 ± 0.035 2 vs.0.315 8 ± 0.033 9,(14.59 ± 2.67)ng/L vs.(10.36 ± 2.31) ng/L],and there were significant differences (P＜0.05).The total effective rate and ulcer healing rate in combined treatment group were higher than those in famotidine group [93.33％ (70/75) vs.80.00％ (60/75),94.67％ (71/75) vs.82.67％ (62/75)] (P＜ 0.05).The incidence of adverse reactions in combined treatment group was slightly higher than that in famotidine group [16.00％(12/75)vs.13.33％ (10/75)],but there was no significant difference between the two groups (P＞0.05).Conclusions Bismuth potassium citrate combined with famotidine in the treatment of peptic ulcer patients can improve gastric acid secretion function,regulate gastric acid-base value,inhibit inflammatory response,improve immune function,and reduce oxidative stress injury.
ABSTRACT
Background: Uric acid nephrolithiasis is characteristically a manifestation of a systemic metabolic disorder. It has a prevalence of about 10% among all stone formers, the third most common type of kidney stone. Uric acid stones form primarily due to an unduly acid urine; less deciding factors are hyperuricosuria and a low urine volume. Aim and objectives: To study and analyze the age and sex distribution of uric acid urolithiasis, to study and identify the predisposing and causative factors and treatment of uric acid urolithiasis. Methods and materials: The materials for the clinical study on radiolucent (uric acid) stones were selected from the cases presenting with pain in loin attended to urology department in King George Hospital, Visakhapatnam from October 2015 to December 2017. The selection of cases was based on clinical symptoms and radiological findings. The number of cases studied was 50. A detailed history, physical examination, blood and urinary examination were done. X-ray KUB, ultrasound KUB, plain CT KUB was done. Patients were treated either medically or surgically depending upon their condition. Results: Out of the 50 patients enrolled, there were 36(72%) male and 14 (28%) female patients. Most of the patients (40%) were in the age group 41-50 years. Pain was the most common symptom (100%) followed by nausea and vomiting. Serum creatinine was normal in 84% of cases. Serum uric acid and Serum electrolytes were normal in all the 50 patients. Urine volume was normal (> 2 litres/24 hrs) in 44% of cases. Urine pH was < 5.5 in 92% and urine uric acid is normal in 100% of cases. In the present study, out of 50 patients, 38(76%) were managed conservatively with potassium citrate and 12 patients were treated with various surgical interventions. Conclusions: Uric acid calculi are more common in men (M: F ratio 2.5:1). Uric acid calculi are caused mostly due to low urinary pH and low urine volume. Type 2 diabetes mellitus and high body Dandamudi Vijay Krishna, Immadi Chandrasekhar. A clinical study on radiolucent (uric acid) stones in tertiary care centre. IAIM, 2019; 6(1): 89-95. Page 90 mass index (BMI) are independent risk factors for uric acid stones. Most of the uric acid calculi can be treated conservatively with potassium citrate (30-40 meq/day) in two divided doses.
ABSTRACT
OBJECTIVE@#Urolithiasis, a common problem in medicine, poses a significant burden with prevalenceof 1-15%. Potassium citrate therapy has become one of the cornerstones of medical stone managementwith hypocitraturia being the most common metabolic problem in stone formers. The authorsdetermined the effects of potassium citrate on urinary metabolic profiles and its impact on stoneburden among Filipino stone formers.@*PATIENTS AND METHODS@#This is a prospective, cohort study in patients seen at the UST Hospital between2016 and 2018. Twenty-four hour urine citrate levels, stone sizes and urine pH pre-therapy and post-therapy were analyzed.@*RESULTS@#Significant changes in urinary citrate, pH and stone sizes were noted as soon as 3 months afterthe onset of therapy. These changes included increase in urinary pH (6.1 to 6.7; p=0.001), increase inurinary citrate (109.1 to 253.4mg/day; p<0.001) and decrease in stone size (0.56 to 0.37cm; p=0.037).The changes in the urine citrate and the changes in the stone size were not correlated using the Pearsoncorrelation scatter plot.@*CONCLUSION@#Potassium citrate therapy provides a significant alkali and citraturic treatment among Filipino stone formers. However, there is no significant correlation between changes in stone size and changes in urine citrate level.
ABSTRACT
Objective To investigate the preventive effect of potassium citrate sustained-release tablets on the formation of adherent stone in ureteral stent-graft after retrograde intrarenal surgery. Methods Patients with upper urinary tract calculi after retrograde intrarenal surgery and without stasis confirmed by color ultrasound were randomly divided into test group and control group. Patients in test group were given potassium citrate sustained release tablets 3 times(1.08 grams each time)orally but those in the control group did not take the drug. Two groups of patients received conventional health education and diet guidance. The formation of adherent stone in ureteral stent-graft during surgical removal of ureteral stent and the adverse reactions during taking the medication 3,6 and 16 weeks after the surgery were compared. Results There were few cases of adherent stone formed 3 weeks after the operation,which can not be statistically analyzed. The incidence of adnexal calculus in the test group 6 and 16 weeks after the operation was significantly lower than that of the control group,which was statistically significant.No serious adverse reactions and complications occurred in the test group during the medication-taking. Conclusions Potassium citrate sustained-release tablet is safe and effective for preventing the formation of adher-ent stone in ureteral stent-graft after upper urinary tract calculi retrograde intrarenal surgery.
ABSTRACT
Objective To explore the clinical efficacy of anti-helicobacter pylori (HP) treatment on patients with type 2 diabetes mellitus and HP infection.Methods A total of 112 type 2 Diabetes patients were diagnosed with HP infection in Combine Traditional Chinese and Western Medicine Hospital of Taizhou from April 2012 to June 2016.These patients were divided into control and treatment group based on the preprandial blood glucose averages from lower to higher hierarchy.Thus,there were 56 patients in each of the two groups.The control group was given Motilium and Talcid for gastric symptoms in addition to anti-diabetes treatment,while the treatment was administered the same treatments as well as the quadruple anti-HP therapy (omeprazole,amoxicillin,clarithromycin and colloidal-bismuth-subcitrate,with Talcid stopped while colloidal-bismuth-subcitrate was administered).The anti-HP lasted for 14 days.The two groups were compared the gastric symptoms,the blood glucose levels,and the HbA1c one month after treatment.Half a year and one year post treatment,the two groups were compared the gastric mucus signs under gastroscopy.Results The improvement rates after treatment with the treatment group in abdominal pain,bloating,regurgitation,belching and diarrhea/constipation were 88.5％ (23/26),83.3％ (25/30),74.1％ (20/27),83.9％ (26/31),82.6％ (19/23),respectively,and with the control group being 29.2％(7/24),32.1％(9/28),28％(7/25),30.3％(10/33),18.2％ (4/22),respectively.The differences between the two groups were significant (x2=8.06,6.62,3.92,7.65,6.66,P＜0.05 or P＜0.01).The control group did not show significant changes in preprandial glucose levels,the glucose levels two hours post meals and the HbA1c(P＞0.05) while the treatment group showed statistically significant changes(P＜0.05 or P＜0.01).The differences in the three indicators after treatment between the two groups were significant (t =4.07,7.85,4.16,P＜ 0.05).The Gastric mucus signs under gastroscopy showed improvements in both groups after treatment.The improvement rates with the treatment group were 86.2％(25/29),86.7％ (13/15),77.8％ (14/18),72.7％ (8/11) respectively,with the control group being 36％ (9/16),27.3％ (3/11),13.3％ (2/15),14.3％ (1/7),respectively.The differences between the two groups were significant (x2 =6.71,4.12,4.38,3.85,P ＜ 0.05 or P＜ 0.01).The effectiveness rate,which was based on combined improvements in gastric symptoms,glucose levels and gastric mucus signs,was 76.8％ with the treatment group and 32.1％ with the control group.The difference was statistically significant (x2 =6.78,P＜0.01).Conclusion Anti-HP treatment can relieve the gastric symptoms,stabilize the glucose levels,and help to reverse the changed gastric mucus.All these can reduce the complications of the diabetes and improve the prognosis of the patients.
ABSTRACT
Resumo A prevalência da nefrolitíase está aumentando em todo o mundo e resulta em ônus significativo para o sistema de saúde. Novos estudos revelam que a formação de cálculos urinários está associada a várias morbidades graves. No entanto, poucos estudos observacionais ou ensaios clínicos randomizados de qualidade demonstraram que intervenções clínicas específicas diminuem a recorrência da nefrolitíase. Portanto, nesta revisão são analisadas as evidências disponíveis da terapia médica expulsiva para cálculos ureterais; avaliam-se os dados da terapêutica não farmacológica, incluindo modificações dietéticas e terapia à base de sucos cítricos; e discute-se a eficácia dos diuréticos tiazídicos no tratamento da hipercalciúria associada à nefrolitíase recorrente.
Abstract The prevalence of kidney stone disease is increasing worldwide with significant health and economic burden. Newer research is finding that stones are associated with several serious morbidities. Yet, few randomized clinical trials or high quality observational studies have assessed whether clinical interventions decrease the recurrence of kidney stones. Therefore, in this review we analyze the available evidence on medical expulsive therapy for ureteral stones; describe the evidence about non-pharmacological stone therapy including dietary modifications and citrus juice-based therapy; and discuss the efficacy of thiazide diuretics for the treatment of hypercalciuria in recurrent nephrolithiasis.
Subject(s)
Humans , Kidney Calculi/therapy , Nephrolithiasis/therapy , Recurrence , Randomized Controlled Trials as Topic , PrevalenceABSTRACT
Objective To investigate the drug effect of children with Dent disease who received therapy of po-tassium citrate and thiazide diuretics and angiotensin -converting enzyme inhibitors(ACEI),and to provide the refe-rence for the clinical treatment.Methods Dent disease patient who were followed -up in Bayi Children′s Hospital Af-filiated to Beijing Military Region General Hospital during the period of July 2006 and March 201 4 were selected.The patients were administered a therapy of potassium citrate associated with thiazide diuretics and ACEI according to the level of proteinuria and calciuria and serum potassium.The underlying changes before and after the treatment were com-pared and analyzed.Results In 1 5 children with Dent disease,they were all male cases,onset age ranged from 3 months to 1 1 years old[(2.62 ±3.1 1 )years old],and the disease duration ranged from 0.50 to 9.50 years old [(2.81 ±2.34)years].The patients were followed up for 0.50 to 7.50 years[(3.61 ±2.62)years].There was a sig-nificantly statistical difference in calcium/creatinine and daily Ca -creat ratio in contrast to before treatment[(0.41 ± 0.1 9)mg/mg vs(0.26 ±0.1 2)mg/mg,t =2.603,P =0.021 ;(6.76 ±2.0)mg/kg vs (4.34 ±1 .97)mg/kg,t =5.265,P =0.000],there was no significantly statistical difference in 24 -hour urinary protein quantity in contrast to before treatment[(0.96 ±0.62)g/24 h vs (0.87 ±0.44)g/24 h,t =1 .01 6,P =0.327].One case with kidney stone and 5 cases with nephrocalcinosis had a negative result of renal ultrasound after treatment.Conclusions Treatment of potassium citrate combination with thiazide diuretics and ACEI can significantly decrease urinary calcium excretion, make a disappearance of kidney stone and nephrocalcinosi,and it may have a role in protecting renal function.Treat-ment of benazepril can not significantly decrease the proteinuria and has no substantial improvement in low molecular weight protein urine.
ABSTRACT
Objective To observe the effect and safety of helicobacter pylori eradication by doxycycline, levofloxacin,bismuth potassium citrate combined with omeprazole.Methods 240 patients who infected helicobacter pylori were selected,and were randomly divided into four groups:treatment group(doxycycline,levofloxacin,bismuth potassium citrate,omeprazole),control group A(doxycycline,levofloxacin,omeprazole),control group B(amoxicillin, clarithromycin,bismuth potassium citrate,omeprazole),control group C (amoxicillin,clarithromycin,omeprazole), 60 patients in each group.Helicobacter pylori eradication treatment for 7 days,patients with gastritis stop after the course of the treatment,peptic ulcer patients continue taking omeprazole 5 weeks after 7 days treatment.All patients stopped medicine 2 weeks accepted 14 carbon breath test.And adverse events were investigated.Results In the treatment group and the control group A,B,C,the helicobacter pylori eradication rates were 93.3%,80.0%,91.7%, 75.0%.Compared with group A,the treatment group helicobacter pylori eradication rate increased significantly(χ2 =4.61,P 0.05).Compared with the treatment group,group B had high inci-dence of oral odor(χ2 =6.56,P <0.05).Compared with the treatment group,group C had high incidence of oral odor (χ2 =5.46,P <0.05).Conclusion Doxycycline,levofloxacin,bismuth potassium citrate combined with omeprazole can improve the helicobacter pylori eradication rate significantly,and with low price,has little side effect,no need of penicillin skin test,can used for the patients poverty or allergic to penicillin.
ABSTRACT
Objective:To study the molecular composition of bismuth potassium citrate. Methods:The content of bismuth was de-termined using a volumetric method, the content of potassium was determined by atomic absorption spectrometry, and the content of cit-rate root was determined by ion chromatography. The structure was predicted using 1 HNMR and the crystal structure was studied using X-diffraction test and scanning electron microscopy. The changes in the percentage ratio of the three components were investigated by accelerated stability tests. Results:On the dried basis, the percentage of the three molecular components was bismuth of 35%-38%, potassium of 7%-11% and root citrate of 49%-52%. The NMR spectra and the data indicated that the product had three isomers with the molecular structure of bismuth∶potassium∶root citrate=2∶2∶2. The X-diffraction test and SEM showed that the three forms of amor-phous, monocrystalline and polycrystalline might exist. The percentage ratio of the three elements before and after the stability test was basically stable. Conclusion:Bismuth potassium citrate may have three crystal forms with the percentage of the three structure parts within a certain range, and the structure is relatively stable.
ABSTRACT
Introducción: las sales de potasio y el flúor han sido usadas en el tratamiento de la hipersensibilidad dentinaria.El objetivo de este estudio fue determinar la eficacia de una crema dental para dientes sensibles con citrato de potasio al 5,6% y fluoruro de sodio al 0,3%, en la disminución de los síntomas de hipersensibilidad dentinaria. Métodos: se obtuvo una muestra aleatoria de 100 personas, hombres y mujeres, mayores de 18 años procedentes del Valle de Aburrá; que presentaran hipersensibilidad dentinaria y cumplieran con los criterios de inclusión. Se diseñó un ensayo clínico aleatorizado, controlado, triple ciego; utilizando un grupo control (placebo) y un grupo experimental (crema dental para dientes sensibles). Las 100personas fueron sometidas a un interrogatorio donde calificaban la intensidad del dolor utilizando la escala visual análoga antes de la intervención; posteriormente en cada persona se seleccionó un diente, el cual fue sometido a la prueba de estímulo térmicoy a la prueba de contacto a presión constante calificando igualmente la intensidad del dolor percibido en cada prueba usando la escala visual análoga. A cada sujeto se le entregó un cepillo dental suave y se le suministró de forma aleatoria el producto que podía contener o el principio activo o el placebo. Los pacientes fueron evaluados y sometidos a las pruebas igual que al inicio delproyecto, en la semana 4 y en la semana 8; registrando los datos obtenidos para cada prueba en los tres tiempos de evaluación. Ninguno de los participantes, es decir; ni el paciente, ni el clínico, ni la estadística conocieron qué tipo de crema se suministróa los pacientes (placebo o componente activo). Resultados: los resultados muestran que en ambos grupos hubo disminución de la hipersensibilidad, pero la crema dental para dientes sensibles muestra mayor disminución de la sensibilidad en todas las mediciones, con las diferentes pruebas aplicadas.
Introduction: potassium and fluoride salts have been used for the treatment of dentine hypersensitivity. The objectiveof this study was to determine the efficacy of a tooth paste with 5.6% of potassium citrate and 0.3% of sodium fluoride for the treatment of dentine hypersensitivity. Methods: a randomized sample of 100 people, male and female from the Valle de Aburrá, older than 18 years of age, with dentine hypersensitivity and who met the inclusion criteria was selected. A randomized triple blind clinical trial was designed, using a control group (placebo), and an experimental group (tooth paste for sensitive teeth).The subjects were given a questionnaire in which they rated the intensity of the pain using the visual analogical scale before the intervention; next, a tooth was selected in each person and subjected to a thermal stimulus test and constant pressure contact test, also rating the intensity of the pain in each test using the visual analogical pain scale. Each subject received a soft toothbrush and the product containing the active principle or the placebo was supplied to them at random. The patients were evaluated and subjected to the same tests used at the beginning of the study, at the fourth week and at the eight week, registering the data obtainedfor each of the tests during the three evaluation periods. None of the participants, that is, neither the doctor, nor the patient nor the statistician knew which toothpaste (active component or placebo) was supplied to the patients. Results: the results showed that there was a decrease in hypersensitivity in both groups; however, the sensitivity toothpaste showed a greater decrease in all the measurements with the different tests applied. Conclusions: although there was a decrease in the symptoms of the placebo group,there was a statistically significant larger decrease in the group that used the sensitivity toothpaste.
Subject(s)
Dentin Sensitivity , Potassium Citrate , Sodium Fluoride , ToothpastesABSTRACT
Objective: To investigate the clinical efficacy and safety of compound bismuth potassium citrate capsules(CBPCC) combined with omeprazole capsules in eradication of Helicobacter pylori (H. pylori) infection. Methods: A total of 240 patients with gastric H. pylori infection were enrolled in this double-blinded, randomized controlled study. Patients in group A(control group) were given a combination of bismuth potassium citrate/tinidazole/clarithromycin tablets and ormprazole capsule(n= 120); those in group B(treatment group) were given compound bismuth potassium citrate capsules and ormprazole capsules (n = 120). H. pylori eradication rates and clinical safety of both treatment regimens were analyzed using SAS 6.12 software system. Results: A total of 236 patients from 6 resreach centers completed in this study, with 117 in group A and 119 in group B. Two patients in the contol group and 8 in the treatment group did not complete the experiment; six patients in the control group were excluded due to other reasons. There were 236 patients entered full analysis sets(FAS), 220 entered per protocol set (PPS), and 236 entered safety analysis sets (SS). FAS showed that the eradication rates of H. pylori were 84.87% in group B and 74.36% in group A(P 0.05), with no severe adverse event found in both groups. The treatment regimen in group B was more cost-effective than that in group A(P<0.05). Conclusion: This study demonstrates that compound bismuth potassium citrate capsules combined with omeprazole capsules have a high efficacy in eradication of H. pylori infection, and it is safe, cost-effective and worth popularizing in clinic.
ABSTRACT
OBJETIVO: Estudar as relações entre a excreção urinária de cálcio, sódio e potássio e a associação sódio/potássio urinários em crianças com hipercalciúria idiopática em dieta habitual, antes e depois da administração de citrato de potássio na dose de 1mEq/kg/dia. MÉTODOS: Foram estudadas prospectivamente 26 crianças: 19 (73 por cento) meninos e sete (27 por cento) meninas com idade entre dois e 13 anos, portadores de hipercalciúria idiopática recém-diagnosticada por dosagem de cálcio em urina de 24 horas >4mg/kg/dia. O citrato de potássio foi administrado na dose de 1mEq/kg/dia. Foram realizadas dosagens séricas e em urina de 24 horas de cálcio (Ca), potássio(K), sódio (Na) e creatinina (Cr), antes e 15 dias depois da administração diária do citrato de potássio. Para comparar os resultados de cálcio/creatinina (Ca/Cr), potássio/creatinina (K/Cr) e sódio/potássio (Na/K) urinários nos dois momentos, aplicou-se o teste não-paramétrico de Wilcoxon. Para a análise das associações entre Ca/Cr e K/Cr e entre Ca/Cr e Na/Cr foi utilizado o coeficiente de correlação de Pearson. Considerou-se significante p<0,05. RESULTADOS: Após o uso de citrato de potássio, ocorreu significativa redução da calciúria e da relação Na/K urinários, bem como elevação na caliúria. Não houve modificação da excreção urinária de sódio. CONCLUSÕES: Em dieta habitual, o citrato de potássio eleva a caliúria e diminui a calciúria em criança hipercalciúricas, sendo um eficaz recurso terapêutico.
OBJECTIVE: Evaluate the relationships among the urinary excretion of calcium (UCa), potassium (UK), sodium (UNa) and the ratio between UNa/UK in children with idiopathic hypercalciuria and a regular diet, before and after 1mEq/kg/day potassium citrate administration. METHODS: 26 children with idiopathic hypercalciuria (UCa>4mg/kg/day) were prospectively studied: 19 (73 percent) boys and seven (27 percent) girls between two and 13 years old. Potassium citrate was administered: 1mEq/Kg/day twice a day for 15 days. Blood and 24-hour urinary determinations of calcium, potassium, sodium and creatinine were done in two periods: before and after the 15-day administration of potassium citrate. The following urinary ratios were analyzed before and after potassium citrate use by Wilcoxon test: calcium/creatinine (UCa/UCr), potassium/creatinine (UK/UCr) and sodium/creatinine (UNa/UCr). The association between UCa/UCr, UK/UCr and Ca/Cr, UCa/UCr and UNa/UK were analyzed by Pearson's correlation. Significance was considered for p<0.05. RESULTS: After potassium citrate use, there were significant reductions of UCa and UNa/UK ratios, as well as a significant increase of UK. The UNa did not change. CONCLUSIONS: Children with idiopathic hypercalciuria and regular diet treated with daily potassium citrate increased their potassium urinary excretion and decreased their calciuria.
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Potassium Citrate/administration & dosage , Calcium , Hypercalciuria/diet therapy , Hypercalciuria/drug therapy , Potassium , SodiumABSTRACT
PURPOSE: Hypocitraturia is cited as one of the risk factors promoting stone formation or recurrence of nephrolithiasis. We estimated the relationship between hypocitraturia and other metabolic abnormalities, such as hypercalciuria, hyperuricosuria and hyperoxaluria. The effects of potassium citrate medication were also investigated. MATERIALS AND METHODS: We selected 706 renal stone patients with hypocitraturia (<320mg/day), who had received extracorporeal shock wave lithotripsy (ESWL) treatment, and examined the relationship between hypocitraturia and other metabolic abnormalities according to sex and age. We also examined the increment effect of urinary citrate and stone-free rate following potassium citrate (Urocitra(R)) medication. RESULTS: Complicated hypocitraturia (coexistence with other metabolic abnormalities) was found in 332 of the 706 patients (47.0%). Of the 706 patients, 242 (34.3%), 112 (15.9%) and 33 (4.7%) had hyperoxaluria, hyperuricosuria and hypercalciuria, respectively. Complicated hypocitraturia was higher in the male than female subjects, and was statistically significant (50.4% vs. 39.8%). In 287 (77%) of the 373 patients who received potassium citrate treatment, the urinary citrate level was increased. The mean urinary citrate level was significantly increased (142.5 vs. 336.2 mg/day) (p<0.01), but the stone free rate was not following the citrate treatment. CONCLUSIONS: Potassium citrate was effective in increasing the urinary citrate level. However, prophylactic effects of potassium citrate against recurrent nephrolithiasis must be proved by appropriate comparative studies.
Subject(s)
Female , Humans , Male , Citric Acid , Hypercalciuria , Hyperoxaluria , Lithotripsy , Nephrolithiasis , Potassium Citrate , Recurrence , Risk Factors , ShockABSTRACT
PURPOSE: We compared the biochemical and clinical presentation of gouty diathesis in patients with uric acid and calcium nephrolithiasis MATERIALS AND METHODS: We retrospectively reviewed biochemical and clinical data from 69 gouty diathesis patients(48 with uric acid stones and 21 with calcium stones) and 57 normal subjects were performed at our institution. RESULTS: Demographic similarity between two groups was a male predominance. Gouty diathesis patients in both groups showed abnormally low urinary pH(<5.5) and propensity for hyperuricemia and hypertriglyceridemia. Gouty arthritis and hyperuricemia was found in 31% and 44% of those with uric acid stones whereas 9.5% and 23.8% in those with calcium stone respectively. In control group, 1 case presented with hyperuricemia and urinary pH at 6.3. Both urinary pH and citrate increased after potassium citrate treatment in both groups. CONCLUSIONS: The two groups of gouty diathesis with either uric acid stone or calcium stones have similar biochemical and clinical features that are characteristic of primary gout. Calcium stone formation in patients with hyperuricemia or persistent acidic urine may represent a latent form of gout. Patients with calcium stones and biochemical feature of gouty diathesis may manifest primary gouty. Both groups are responsive to potassium citrate treatment.
Subject(s)
Humans , Male , Arthritis, Gouty , Calcium , Citric Acid , Disease Susceptibility , Gout , Hydrogen-Ion Concentration , Hypertriglyceridemia , Hyperuricemia , Nephrolithiasis , Potassium Citrate , Retrospective Studies , Uric AcidABSTRACT
Potassium citrate therapy caused a sustained increase in urinary pH and potassium, and restored urinary citrate to normal levels. No significant changes occurred in urinary uric acid, oxalate, sodium or phosphorus levels. Owing to these physiological changes, uric acid solubility increased, urinary saturation of calcium oxalate decreased and the propensity for spontaneous nucleation of calcium oxalate was reduced to normal. Therefore, the Physicochemical environment of urine following treatment become less conductive to the crystallization of calcium oxalate or uric acid. Twenty six patients with uric acid nephrolithiasis with or without calcium nephrolithiasis underwent treatment and long-term preventive management (mean of 20.8 months) with potassium citrate. Urinary pH increased from acid (5.0-5.5) to normal (6.5-7.0) during treatment. During the period of preventive management, stones were not developed.